Bull
$5.26
シナリオ価格
$5.265
-0.225 (-4.27%)終値時点
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Unicycive Therapeutics is currently not a strong buy due to recent FDA setbacks and price volatility. The stock is priced at $5.265, with an RSI of 39.161 indicating potential oversold conditions. However, the company has faced significant challenges, including a 37% drop in stock price after receiving a Complete Response Letter from the FDA, which highlights ongoing manufacturing issues. The forward P/E ratio is 3.4447, suggesting potential undervaluation, but the risks are substantial given the recent regulatory hurdles and the company's negative net income of $12.823 million in Q1 2026.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Block & Leviton Investigates Unicycive for Potential Violations

Unicycive Under Investigation for Securities Violations

Unicycive Under Investigation for Securities Violations

Unicycive Faces Investor Lawsuit Investigation

Block & Leviton Investigates Unicycive Therapeutics for Securities Violations
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Unicycive Therapeutics is currently not a strong buy due to recent FDA setbacks and price volatility. The stock is priced at $5.265, with an RSI of 39.161 indicating potential oversold conditions. However, the company has faced significant challenges, including a 37% drop in stock price after receiving a Complete Response Letter from the FDA, which highlights ongoing manufacturing issues. The forward P/E ratio is 3.4447, suggesting potential undervaluation, but the risks are substantial given the recent regulatory hurdles and the company's negative net income of $12.823 million in Q1 2026.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。